PROCEPT BioRobotics (NASDAQ:PRCT) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

PROCEPT BioRobotics (NASDAQ:PRCT) released its quarterly earnings data on Tuesday. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.01), FiscalAI reports. PROCEPT BioRobotics had a negative return on equity of 30.10% and a negative net margin of 32.53%.The company had revenue of $94.50 million for the quarter, compared to the consensus estimate of $92.77 million. During the same period in the prior year, the business earned ($0.35) earnings per share. The business’s revenue was up 19.3% compared to the same quarter last year.

Here are the key takeaways from PROCEPT BioRobotics’ conference call:

• Q2 revenue rose 19% year over year to $94.5 million, supported by 65 HYDROS system placements, stronger pricing, and 32% growth in U.S. system revenue. Management maintained its full-year revenue guidance of $390 million to $410 million.
• U.S. procedures increased 21% to more than 13,100 but came in below expectations, primarily because of softness in legacy AquaBeam accounts. Full-year procedure guidance was reduced to 54,000–56,000, with the low end assuming no improvement in AquaBeam utilization.
• HYDROS accounts are generating significantly more procedures per account than legacy AquaBeam sites, while launch-team-supported accounts are showing faster time to first case and stronger early utilization. PROCEPT is accelerating replacements, completing 14 in Q2 and now expecting approximately 40 for the full year.
• Operating expenses increased to $89.8 million, driving a $26.9 million net loss and an $11.3 million adjusted EBITDA loss in Q2. The company raised full-year operating expense guidance to $355 million–$360 million, although it still expects positive adjusted EBITDA in Q4.
• The American Urological Association strengthened its recommendation for Aquablation, and PROCEPT completed enrollment of all 280 patients in the WATER IV randomized prostate cancer trial. The company also received FDA IDE approval for a second randomized trial comparing Aquablation with active surveillance.

PROCEPT BioRobotics Stock Down 0.4%

Shares of NASDAQ:PRCT traded down $0.07 during midday trading on Thursday, hitting $19.27. 1,283,519 shares of the stock were exchanged, compared to its average volume of 1,612,072. The company has a market capitalization of $1.10 billion, a PE ratio of -9.93 and a beta of 0.89. PROCEPT BioRobotics has a 52-week low of $16.67 and a 52-week high of $42.71. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.51 and a current ratio of 6.73. The business’s fifty day simple moving average is $21.85 and its two-hundred day simple moving average is $24.89.

Institutional Investors Weigh In On PROCEPT BioRobotics

Several institutional investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd raised its position in PROCEPT BioRobotics by 436.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock valued at $29,000 after acquiring an additional 746 shares in the last quarter. US Bancorp DE increased its stake in shares of PROCEPT BioRobotics by 175.7% during the 3rd quarter. US Bancorp DE now owns 1,693 shares of the company’s stock worth $60,000 after purchasing an additional 1,079 shares during the last quarter. Lazard Asset Management LLC raised its holdings in shares of PROCEPT BioRobotics by 90.7% during the 2nd quarter. Lazard Asset Management LLC now owns 1,703 shares of the company’s stock valued at $98,000 after purchasing an additional 810 shares in the last quarter. Osaic Holdings Inc. lifted its stake in shares of PROCEPT BioRobotics by 20.3% in the 2nd quarter. Osaic Holdings Inc. now owns 2,001 shares of the company’s stock valued at $115,000 after purchasing an additional 337 shares during the last quarter. Finally, Kestra Advisory Services LLC acquired a new stake in shares of PROCEPT BioRobotics in the 4th quarter valued at $68,000. 89.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on PRCT shares. UBS Group lowered shares of PROCEPT BioRobotics from a “buy” rating to a “neutral” rating and set a $20.00 price target on the stock. in a report on Tuesday, July 28th. Robert W. Baird set a $20.00 target price on shares of PROCEPT BioRobotics in a research note on Wednesday. TD Cowen decreased their target price on PROCEPT BioRobotics from $34.00 to $28.00 and set a “buy” rating for the company in a research report on Wednesday. Leerink Partners downgraded PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $31.00 to $29.00 in a report on Thursday, June 11th. Finally, William Blair lowered PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $28.00.

Key Headlines Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: PROCEPT reported second-quarter revenue of $94.5 million, up 19.3% year over year and above the $92.77 million consensus estimate. The results initially supported the stock. PROCEPT BioRobotics Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management guided to fiscal 2026 revenue of $390 million to $410 million, a range surrounding analysts’ $397.2 million estimate and indicating continued growth potential.
• Neutral Sentiment: Brokerages have assigned PROCEPT a consensus “Hold” rating, reflecting a balance between the company’s revenue growth and ongoing profitability concerns. PROCEPT Given Consensus Hold Rating
• Negative Sentiment: Second-quarter adjusted loss was $0.47 per share, slightly worse than the $0.46 expected and wider than the $0.35 loss a year earlier. PROCEPT remains unprofitable, with analysts expecting a full-year loss.
• Negative Sentiment: Wells Fargo downgraded PROCEPT from “Overweight” to “Equal Weight” and set a $19 price target, citing limited upside after recent weakness. Wells Fargo Downgrade
• Negative Sentiment: Multiple law firms publicized a securities class action covering investors who purchased shares from February 28, 2024, through February 25, 2026. The allegations concern underperforming handpiece sales, excess customer inventory and late-quarter bulk discounts that may have overstated demand. The lead-plaintiff deadline is September 22, 2026. These are allegations, not established findings, but the legal overhang could weigh on investor sentiment. PRCT Investor Alert

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.